Perceptive Capital Solutions (NASDAQ:PCSC – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Valuation & Earnings
This table compares Perceptive Capital Solutions and Neuphoria Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Perceptive Capital Solutions | N/A | N/A | $840,000.00 | ($0.06) | -199.17 |
| Neuphoria Therapeutics | $15.65 million | 1.36 | -$370,000.00 | ($11.06) | -0.36 |
Institutional and Insider Ownership
15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 22.1% of Perceptive Capital Solutions shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Perceptive Capital Solutions and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Perceptive Capital Solutions | N/A | -2.70% | -0.84% |
| Neuphoria Therapeutics | N/A | -76.93% | -54.76% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Perceptive Capital Solutions and Neuphoria Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Perceptive Capital Solutions | 1 | 0 | 0 | 0 | 1.00 |
| Neuphoria Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 431.65%. Given Neuphoria Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Perceptive Capital Solutions.
Risk & Volatility
Perceptive Capital Solutions has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Summary
Neuphoria Therapeutics beats Perceptive Capital Solutions on 7 of the 12 factors compared between the two stocks.
About Perceptive Capital Solutions
Perceptive Capital Solutions Corp is a blank check company. It formed for the purpose of entering into a combination with one or more businesses or entities. Perceptive Capital Solutions Corp is based in NEW YORK.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Perceptive Capital Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perceptive Capital Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
